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Abstract 
In eukaryotic cells, the shortening and removal of the poly(A) tail (deadenylation) of 
cytoplasmic mRNA is a key event in regulated mRNA degradation. A major enzyme 
involved in deadenylation is the Ccr4-Not deadenylase complex, which can be recruited to its 
target mRNA by RNA-binding proteins or the miRNA repression complex. In addition to six 
non-catalytic components, the complex contains two enzymatic subunits with ribonuclease 
activity: Ccr4 and Caf1 (Pop2). In vertebrates, each deadenylase subunit is encoded by two 
paralogues: Caf1, which can interact with the anti-proliferative protein BTG2, is encoded by 
CNOT7 and CNOT8, while Ccr4 is encoded by the highly similar genes CNOT6 and 
CNOT6L. Currently, it is unclear whether the catalytic subunits work cooperatively, or 
whether the nuclease components have unique roles in deadenylation. We therefore 
developed a method to express and purify a minimal human BTG2-Caf1-Ccr4 nuclease sub-
complex from bacterial cells. By using chemical inhibition and well-characterised 
inactivating amino acid substitutions, we demonstrate that the enzyme activities of Caf1 and 
Ccr4 are both required for deadenylation in vitro. These results indicate that Caf1 and Ccr4 
cooperate in mRNA deadenylation and suggest that the enzyme activities of Caf1 and Ccr4 
are regulated via allosteric interactions within the nuclease module. 
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Introduction 
In eukaryotic cells, virtually all mature cytoplasmic mRNA is characterised by the presence 
of a 3’ poly(A) tail. This feature is important for translation and mRNA stability [1, 2]. The 
shortening and removal of the poly(A) tail (deadenylation) is the initial and often rate-
limiting step in regulated mRNA decay.  Subsequent decapping exposes both ends of the 
mRNA to exonucleolytic degradation involving the Xrn1 nuclease (5’-3’) and/or the 
multisubunit exosome complex (3’-5’ decay) [3-5].  
The majority of mRNA deadenylation is carried out by the Pan2-Pan3 and Ccr4-Not enzyme 
complexes [6-9]. The Ccr4-Not complex contains two catalytic and six accessory subunits [8, 
10, 11]. The ribonuclease activity of the Ccr4 subunit (encoded by the CNOT6 and CNOT6L 
paralogues in vertebrates) is provided by an endonuclease-exonuclease-phosphatase (EEP) 
domain [12-15]. Its amino-terminal leucine-rich repeat (LRR) domain binds directly to the 
Caf1 catalytic subunit (encoded by CNOT7 and CNOT8 in vertebrates), which is 
characterised by an RNAseD DEDD domain [15-18]. The nuclease subunits are tethered to 
the non-catalytic subunits via interactions between Caf1 and the central MIF4G domain of 
the large subunit, CNOT1 (Not1) [19, 20]. This subunit also plays critical roles in the 
selective recruitment of the Ccr4-Not complex to target mRNAs as exemplified, for instance, 
by interactions with the RNA-binding proteins tristetraprolin (TTP) and Nanos [21-24]. 
Moreover, CNOT1 and the non-catalytic RQCD1 (Rcd1/CNOT9) subunit interact with 
TNRC6 (GW182) thereby facilitating miRNA-mediated mRNA deadenylation and 
translational repression [25-29]. In addition to selective recruitment to target mRNAs, the 
Ccr4-Not complex can also be recruited to mRNA via interactions with the conserved amino-
terminal BTG domain of Tob1 and Tob2 [30-33]. These highly related proteins contain a 
PAM2 motif facilitating binding to the carboxy-terminal domain of cytoplasmic poly(A)-
binding protein [30]. However, other members of the BTG/TOB family of proteins also 
interact with the Caf1 subunit, including BTG2, but do not possess a PAM2 motif [34-39]. 
The BTG2 protein is required for the deadenylation of at least several mRNAs [35]. 
Moreover, its anti-proliferative activity requires the interaction with Caf1, suggesting that the 
ability of BTG2 to inhibit cell cycle progression is mediated via deadenylation by Ccr4-Not 
[39]. 
Currently, it is unclear whether the Ccr4 and Caf1 nuclease subunits have specialised roles, or 
whether they cooperate in mRNA deadenylation. In the yeast Saccharomyces cerevisiae, 
Ccr4 is the main catalytic subunit [12, 13]. In agreement with this notion, point mutations that 
inactivate the catalytic activity of Caf1 complement the phenotype of Caf1 cells and do not 
affect deadenylation [40]. However, the enzyme activity of Caf1 contributes to deadenylation 
in other eukaryotes, including the fission yeast Schizosaccharomyces pombe and the 
filamentous yeast Aspergillus nidulans [41, 42]. In human cells, there are marked differences 
in the genome-wide expression profiles of Caf1 and Ccr4-knockdown cells, respectively, 
suggesting that the Caf1 and Ccr4 subunits have unique roles in the regulation of mRNA 
levels [43, 44]. Interestingly, the active sites of Caf1 and Ccr4 are not in close proximity in 
the x-ray structure of a minimal nuclease module consisting of the budding yeast Not1 
MIF4G domain, Caf1 and Ccr4 [19]. 
To obtain more insight into the mechanism of deadenylation and the relative contributions of 
the Caf1 and Ccr4 nuclease subunits, we developed a method for the expression and 
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purification of a human BTG2-Caf1-Ccr4 nuclease sub-complex. By using well-characterised 
single amino acid substitutions that abolish the nuclease activity of Caf1 or Ccr4, we 
demonstrate that both catalytic subunits are required for deadenylation. This conclusion was 
corroborated by using small molecules that selectively inhibit Caf1 and do not affect the 
activity of the catalytic domain of Ccr4. 
 
Materials and Methods 
Plasmids, DNA cloning and site-directed mutagenesis 
Plasmids pQE80L (Qiagen) containing codon-optimised cDNAs (Genscript) encoding human 
Caf1/CNOT7 or Ccr4b/CNOT6LLRR (Ccr4b/CNOT6L lacking residues 1-155) were 
described before [45]. A plasmid containing a codon-optimised cDNA fragment encoding 
human Ccr4a/CNOT6 lacking the amino-terminal leucine-rich repeat domain (amino acids 1-
155) was obtained using standard PCR techniques and cloned into the multiple cloning site of 
pQE80L (Qiagen) using the BamHI and SalI restriction endonucleases. A human BTG2 
cDNA containing a BamHI site at the 5’ end and an XhoI site at the 3’ end was amplified 
using standard techniques and inserted into the BamHI and SalI restriction sites of pQE80L 
(Qiagen). 
Dual expression vectors containing the CNOT6L and CNOT7 cDNAs were generated by first 
inserting a PCR-generated CNOT7 cDNA fragment containing a 5’ BamHI and 3’ SalI 
restriction site into the BglII and XhoI sites of multiple cloning site 2 of vector pACYCDuet-
1 (Merck Millipore). Then, a CNOT6L cDNA (generated by PCR) was subcloned in-frame 
with the hexahistidine tag coding sequences into multiple cloning site 1 of the same vector 
using the BamHI and SalI restriction sites. Alternatively, a CNOT6L cDNA fragment 
containing a 5’ NcoI site was amplified using standard PCR techniques and subcloned into 
the NcoI and SalI sites of multiple cloning site 1 facilitating the expression of untagged 
Ccr4b/CNOT6L. GST-CNOT6L or GST-CNOT6 fragments were amplified using standard 
PCR techniques and subcloned into the NcoI and NotI sites of multiple cloning site 1. The 
generation of cDNAs encoding GST-Ccr4b/CNOT6L and GST-Ccr4a/CNOT6 was facilitated 
by subcloning the CNOT6L and CNOT6 cDNAs into the BamHI and SalI sites of vector 
pGEX4T1 (GE Healthcare Life Sciences). 
Site-directed mutagenesis resulting in the amino acid substitutions D40A (Caf1/CNOT7) and 
E240A (Ccr4a/CNOT6 and Ccr4b/CNOT6L) was carried out using a modified Quikchange 
procedure (Stratagene). Oligonucleotide sequences used for mutagenesis were designed using 
the PrimerX tool (http://www.bioinformatics.org/primerx/). 
 
Protein expression and purification 
The human Caf1/CNOT7, Ccr4b/CNOT6LLRR and Ccr4a/CNOT6LRR enzymes were 
expressed and purified from Escherichia coli BL21 (DE3) using procedures described before 
[45]. The trimeric nuclease module was purified following co-expression of His•BTG2, Caf1, 
and Ccr4 or GST•Ccr4 in E. coli strain BL21 (DE3). Cells carrying plasmids pQE80L-BTG2 
and pACYCDuet-1/CNOT6L/CNOT7 were grown in lysogeny broth containing 34 µg/ml 
chloramphenicol and 100 µg/ml ampicillin. Protein expression (4 L culture) was induced by 
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the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG; 0.2 mM final concentration) 
for 3 h at 30°C or o/n at room temperature (0.1 mM IPTG, final concentration). Cells were 
harvested by centrifugation and resuspended in 0.01 vol lysis buffer (20 mM Tris-HCl pH 7.8, 
500 mM NaCl, 10% glycerol, 2 mM β-mercaptoethanol). Cells were lysed on ice using a 
Qsonica XL2000 sonicator (40% amplitude) using five 30 sec on/30 sec off cycles. The crude 
lysate was cleared by centrifugation using a Sorvall SS-34 rotor spun at 10 000 rpm, 4ºC for 
30 minutes. Protein complexes were purified from the soluble lysate using Co2+-agarose (1 
ml bed volume) as described before [45]. Then, peak fractions containing His•BTG2-Caf1-
Ccr4 complexes were further purified by gel filtration (Superdex 200 16/60; GE Healthcare 
Life Sciences) to separate His•BTG2-Caf1 dimeric complexes and trimeric His•BTG2-Caf1-
Ccr4 complexes. The column was run in buffer containing 20 mM Tris-HCl (pH 7.8), 
150 mM NaCl, 5% (v/v) glycerol and 1 mM β-mercaptoethanol while collecting 2.5 ml 
fractions. Alternatively, Pierce GST spin columns (Thermo Scientific) were used as a second 
affinity step to isolate trimeric His•BTG2-Caf1-GST•Ccr4 complexes following the 
manufacturer’s instructions. Purified proteins were stored in small aliquots at -80°C. Protein 
concentrations were determined using the Protein Assay Reagent (Bio-Rad). 
 
SDS-PAGE and immunoblotting 
Proteins were analysed by 14% SDS-PAGE followed by staining with Coomassie Blue 
(SimplyBlue Safestain) or SYPRO Ruby as per the manufacturer’s instructions (Life 
Technologies). For immunoblotting, proteins were transferred to nitrocellulose membranes. 
Anti-CNOT7, anti-CNOT6L and anti-CNOT6 polyclonal primary antibodies were obtained 
by immunising rabbits with peptide-conjugated KLH (Eurogentec). BTG2 was detected using 
rabbit polyclonal antibody H-50 (Santa Cruz). Horseradish peroxidase-conjugated secondary 
antibodies (Santa Cruz) were used for detection in combination with an enhanced 
chemiluminescence detection kit (Pierce). Signals were captured using a Fujifilm LAS-4000 
digital imaging system. Image analysis was carried out using ImageJ 
(http://imagej.nih.gov/ij/). 
 
Analysis of deadenylase activities 
Fluorescence-based analysis of deadenylase activity was carried out as described [45]. Briefly, 
reactions (10 µl; 20 mM Tris-HCl pH 7.9, 50 mM NaCl, 2 mM MgCl2, 10% glycerol, 1 mM 
β-mercaptoethanol in nuclease-free water) containing 1.0 M 5’-Flc-labelled RNA substrate 
and the indicated amount of protein were incubated at 30°C for 60 min. Then, reactions were 
stopped by the addition of 10 µl SDS/probe mix containing 1% SDS, and a five-fold molar 
excess of 3’ labelled DNA probe. The 5’-fluorescein-CCU UUC CAA AAA AAA A-3’ RNA 
substrate oligonucleotide (HPLC purified) and the 5’-TTT TTT TTT GGA AAG G-3’ DNA 
probe containing a 3’ tetramethylrhodamine (TAMRA) label (HPLC purified) were obtained 
from Eurogentec. Fluorescence intensity was measured at 25°C using a BioTek Synergy HT 
plate reader with 96 or 384 U-shaped black multiwell plates. Filter sets used were: 485±20 
nm (excitation) and 528±20 nm (detection).  
For gel-based analysis of reaction products, 6 l RNA loading buffer (95% formamide, 0.025% 
bromophenol blue, 0.025% xylene cyanol FF, 0.025% sodium dodecylsulfate and 5 mM 
EDTA) was added to a 5 µl reaction sample, and heated for 3 min at 85C. Part of the RNA 
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mixture (3 l) was analysed by denaturing polyacrylamide gel electrophoresis using a 20% 
acrylamide:bisacrylamide (19:1)/50% (w/v) urea gel (8 cm×8 cm×0.1 cm). The gel was run 
in 0.5×TBE at 200V using an Xcell mini system (Life Technologies). 5’-fluorescein-labelled 
RNA was visualised by epifluorescence using a Fujifilm LAS-4000 system.  
 
Chemicals 
Selective small molecule inhibitors of the Caf1/CNOT7 enzyme NCC-00007277 (N-(4-
chlorophenyl)-5-[2-[[2-(2-furyl)-1-methyl-ethyl]amino]-2-oxo-ethyl]sulfanyl-1,3,4-
thiadiazole-2-carboxamide; ChemDiv, cat no. F736-0540), NCC-00001590 (N-[6-
(isobutylsulfamoyl)-1,3-benzothiazol-2-yl]-2-methyl-benzamide; ChemDiv, cat no. G786-
1651), and NCC-00039069 (N'-[2-[4-[(2-methoxyphenyl)carbamoyl]anilino]-2-oxo-ethyl]-N-
(2-thienylmethyl)oxamide; Enamine, cat no. Z227823544) were described before [45]. 
 
Results 
Purification of a human BTG2-Caf1-Ccr4b deadenylase sub-complex  
To obtain more insight into deadenylation by the Ccr4-Not complex and the relative 
contributions of the Caf1 and Ccr4 nuclease subunits, we evaluated several strategies for the 
expression and purification of the nuclease sub-complex containing the Caf1 and Ccr4 
catalytic components. Our attempt to reconstitute a Caf1-Ccr4 complex by purifying the 
isolated components was unsuccessful, because GST fusion proteins of full length Ccr4 were 
insoluble in bacterial lysates. Co-expression of His or GST-tagged Ccr4b (CNOT6L) and 
Caf1 was also unsuccessful, because we were only partially able to remove a putative 
chaperone contamination by treatment with ATP and urea. We then co-expressed Caf1, 
Ccr4b and His-tagged BTG2, whose interaction with Caf1 is well characterised (Figure 1A, 
1B) [34-38]. Following consecutive immobilised metal affinity chromatography and gel 
filtration, trimeric BTG2-Caf1-Ccr4b and dimeric BTG2-Caf1 complexes were obtained 
(Figure 1C, 1D).  
As an alternative purification strategy, we also co-expressed GST•Ccr4b, Caf1 and His-
tagged BTG2 (Figure 1E). Following sequential immobilised metal and glutathione affinity 
chromatography, a highly purified trimeric BTG2-Caf1-Ccr4b complex was obtained (Figure 
1F). This two-step procedure is rapid and multiple purifications can be carried out in parallel. 
 
Comparison of the deadenylase activities of Caf1, BTG2-Caf1, Ccr4b LRR and the 
trimeric BTG2-Caf1-Ccr4b complex 
As a first step to evaluate the contributions of the Caf1 and Ccr4 subunits to the ribonuclease 
activity of the Ccr4-Not complex, we compared the deadenylase activity of the dimeric BTG-
Caf1 complex, the trimeric BTG2-Caf1-Ccr4 module and those of Caf1 and Ccr4b lacking 
the LRR domain (Ccr4b LRR). Analysis of the purified proteins by SDS-PAGE indicated 
that they were of comparable purity, although the concentration of the trimeric BTG2-Caf1-
Ccr4 module was somewhat overestimated as compared to the other purified proteins (Figure 
2A). This was confirmed by immunoblot analysis (Figure 2B). We then determined the 
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activity of the protein samples using a recently developed fluorescence-based deadenylase 
assay [45]. The method is based on the incubation of enzyme and a 5’ fluorescein (Flc)-
labelled RNA substrate, followed by the addition of a complementary DNA probe containing 
a 3’ carboxytetramethylrhodamine (TAMRA) label. In the absence of deadenylase activity, 
addition and subsequent annealing of the probe will result in quenching of Flc fluorescence, 
due to the close proximity of the TAMRA moiety. By contrast, efficient annealing of the 
DNA probe is prevented when the substrate is degraded, thus allowing detection of Flc-
mediated fluorescence [45]. Using this assay, we found that Caf1 and Ccr4b LRR both 
displayed deadenylase activity, as expected. However, we found that Caf1 displays 
significantly higher activity as compared to the catalytic domain of Ccr4b (Figure 2C). 
Unexpectedly, the dimeric BTG2-Caf1 complex displayed increased activity as compared to 
monomeric Caf1. In addition, the activity of the trimeric BTG2-Caf1-Ccr4b complex was 
more active than any of the other purified components, despite the fact that its concentration 
was somewhat lower (Figure 2C). Taken together, we concluded that the enzyme activities of 
Caf1 and Ccr4 both contribute to deadenylation within the context of the nuclease sub-
complex. 
 
The catalytic activities of Caf1 and Ccr4b are both required for deadenylation by the 
BTG2-Caf1-Ccr4b nuclease module 
To establish the relative contributions of the Caf1 and Ccr4b subunits to deadenylation by the 
trimeric nuclease module, we used site-directed mutagenesis to introduce the amino acid 
substitutions D40A and/or E240A, which abolish the catalytic activity of Caf1 and Ccr4b, 
respectively. We then purified BTG2-Caf1-Ccr4b complexes containing either wild type or 
inactive Caf1 and/or Ccr4b using subsequent immobilised metal and glutathione affinity 
chromatography (Figure 3A). Analysis of the purified proteins by SDS-PAGE indicated that 
the protein complexes were of comparable purity and concentration (Figure 3A), which was 
confirmed by immunoblot analysis (Figure 3B). Surprisingly, the deadenylase activity of 
complexes containing either inactive Caf1 (D40A) or inactive Ccr4b (E240A) was 
undetectable and indistinguishable from the background signal observed with complexes in 
which both Caf1 and Ccr4 were inactive (Figure 3C). Product analysis by denaturing 
polyacrylamide gel electrophoresis indicated that these observations were not due to artefacts 
of the fluorescent assay (Figure 3D). Together, these findings indicate that both Caf1 and 
Ccr4b are required for deadenylation by a trimeric BTG2-Caf1-Ccr4b nuclease sub-complex. 
 
Selective inhibitors of Caf1 inhibit the deadenylase activity of a BTG2-Caf1-Ccr4b 
trimeric nuclease module  
To explore the requirement of Caf1 in deadenylation by a trimeric BTG2-Caf1-Ccr4b 
complex in more detail, we used selective Caf1 inhibitors [45]. Using a panel of Caf1 
inhibitors identified before, we selected three compounds that are unable to inhibit the 
activity of the Ccr4 LRR enzyme [45]. Because of their potency versus isolated Caf1 (IC50 
values in the range of 100-140 M; Figure 4A), we used a single concentration of 300 M for 
each compound. As shown (Figure 4A and 4B), the most potent compound (NCC-1590; 
IC50=98.7±10.9 µM) abolished the activity of the trimeric complex. Lower potency 
compounds NCC-39069 (IC50=129±18.8 µM) and NCC-7277 (IC50=137±20.3 µM) partially 
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inhibited the activity of the BTG2-Caf1-Ccr4b complex. These results indicate that Caf1 
makes a major contribution to the deadenylase activity of the BTG2-Caf1-Ccr4b complex and 
are consistent with the conclusion that Caf1 is required for the activity of the trimeric 
complex. 
 
Deadenylation by the BTG2-Caf1-Ccr4a complex 
To confirm the requirement of the nuclease subunits further, we next focussed on the Ccr4a 
(CNOT6) subunit, which is highly related to Ccr4b (78% identity, 88% similarity). We 
expressed and purified Ccr4a lacking the LRR domain (Ccr4a LRR) as well as a 
catalytically inactive mutant (Figure 5A). The deadenylase activity of Ccr4a LRR was 
readily detectable and appeared significantly increased as compared to the activity of 
Ccr4b LRR (Figure 5B and 5C). We then purified BTG2-Caf1-Ccr4a complexes containing 
either wild type or inactive Caf1 and/or Ccr4 using subsequent immobilised metal and 
glutathione affinity chromatography (Figure 5D).  Again, analysis of the purified proteins by 
SDS-PAGE indicated that the protein complexes were of comparable purity and 
concentration (Figure 5D), which was confirmed by immunoblot analysis (Figure 5E). In 
addition, as was the case when characterising the BTG2-Caf1-Ccr4b nuclease modules, the 
deadenylase activity of BTG2-Caf1-Ccr4a complexes containing either inactive Caf1 (D40A) 
or inactive Ccr4a (E240A) was undetectable and indistinguishable from the background 
signal observed with complexes in which both Caf1 and Ccr4a were inactive (Figure 5F). 
Again, product analysis by denaturing polyacrylamide gel electrophoresis indicated that these 
observations were not due to artefacts of the fluorescent assay (Figure 5G).  
Taken together, the results demonstrate that (1) a complex containing Caf1 and Ccr4 is more 
active than its isolated components;  and (2) both Caf1 and Ccr4 are required for 
deadenylation by a trimeric BTG2-Caf1-Ccr4 nuclease sub-complex in vitro. In addition, in 
agreement with a positive role in deadenylation [35], BTG2 does not appear to inhibit the 
enzyme activity of Caf1. 
 
Discussion 
The Ccr4-Not complex is a major deadenylase enzyme involved in the shortening and 
removal of the poly(A) tail of cytoplasmic mRNA. It is equipped with two catalytic subunits 
containing ribonuclease activity that display selectivity for poly(A) residues. However, it has 
been unclear whether the catalytic nuclease subunits cooperate in deadenylation, or whether 
they have unique roles. Here, we provide evidence that the ribonuclease activities of Caf1 and 
Ccr4 are both required for deadenylation. The findings are based on a newly developed 
strategy for the expression and purification of a trimeric nuclease complex composed of the 
human anti-proliferative BTG2 protein, Caf1 and Ccr4. This allowed the analysis of purified 
complexes containing one inactive nuclease subunit (either Caf1 or Ccr4) or two inactive 
subunits (both Caf1 and Ccr4). Three independent approaches indicate that the enzyme 
activities of both subunits are required: (i) the analysis of BTG2-Caf1-Ccr4b complexes; (ii) 
the use of selective inhibitors of Caf1 [45], which are able to completely inhibit the activity 
of trimeric BTG2-Caf1-Ccr4b; and (iii) the analysis of BTG2-Caf1-Ccr4a nuclease modules. 
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It should be noted that even at the highest enzyme concentrations, multiple rounds of 
catalysis (>10) are required for the complete degradation of the substrate. 
The conclusion that the enzyme activities of both Caf1 and Ccr4 are required is surprising, 
because several results indicated that the nuclease subunits have unique roles. First, the 
catalytic activity of Caf1 is dispensable in Saccharomyces cerevisiae, indicating that the 
enzyme activity of Ccr4 is sufficient for deadenylation [12, 13, 40]. In addition, knockdown 
of the Caf1 paralogues in human cells differentially affects gene expression as compared to 
knockdown of the Ccr4 paralogues [43, 44]. Also, the isolated, monomeric versions of Caf1 
protein and the purified EEP domain of Ccr4 are active ribonuclease enzymes. Finally, the 
structural analysis of a minimal nuclease module composed of the yeast MIF4G domain of 
Not1, Caf1 and Ccr4 indicated that the active sites of Caf1 and Ccr4 are not in close 
proximity [19]. While we only investigated the role of a nuclease sub-complex, we believe 
that it is likely that both enzyme activities are also required in the context of the complete 
Ccr4-Not complex, although we cannot exclude that the accessory subunits of the Ccr4-Not 
complex modulate the activity of the nuclease module. Regardless, the results reported here 
reveal an unexpected property of the nuclease sub-complex. 
Interestingly, Petit et al. found that the catalytic pocket of Caf1 is occluded by its C-terminus 
(residues G274-E280) in the x-ray structure of Caf1 in complex with the MIF4G domain of 
CNOT1 [20]. While the authors indicated that this simply may be due to the conditions 
required for crystal packing, they also raised the possibility that this was a potential 
mechanism for regulation of the deadenylase activity of Caf1. 
Analysis of the activities of monomeric subunits indicated that the deadenylase activity 
associated with the EEP domain of Ccr4a is more active as compared to the Ccr4b nuclease 
domain, despite their high overall similarity. In addition, we noticed that the BTG2-Caf1 
dimeric complex displays a higher activity as compared to the isolated Caf1 protein, while 
the trimeric BTG2-Caf1-Ccr4 complexes display even higher activity. This was surprising, as 
it was reported that BTG2 is able to inhibit the deadenylase activity of Caf1 [38]. However, 
our finding is in agreement with a role for BTG2 as a positive regulator of mRNA 
deadenylation as well as with the observation that the BTG domain of Tob1 is unable to 
inhibit the activity of Caf1 [33, 35]. 
Taken together, our data support a model in which the ribonuclease subunits of the Ccr4-Not 
complex cooperate in deadenylation. We speculate that alternate action of Caf1 and Ccr4 is 
required. The findings that a complex containing Caf1 and Ccr4 is more active than its 
isolated components as well as the observations that the enzyme activities of both Caf1 and 
Ccr4 are required for deadenylation by a BTG2-Caf1-Ccr4 complex suggest a model wherein 
the catalytic activities of Caf1 and Ccr4 are regulated via allosteric interactions within the 
nuclease module.  
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Figure legends 
 
Figure 1. Purification of a human BTG2-Caf1-Ccr4b deadenylase sub-complex 
(A) Diagram of the nuclease subunits Ccr4 and Caf1, and the Caf1-interacting protein BTG2. 
Shaded in light grey are the DEDD and EEP nuclease domains of Caf1 and Ccr4, respectively. 
The BTG and leucine-rich repeat (LRR) interaction domains of BTG2 and Ccr4, respectively, 
are indicated in dark grey. (B) Purification strategy based on co-expression of His•BTG2, 
Caf1 and Ccr4b followed by immobilised-metal affinity and size exclusion chromatography. 
(C) Elution profile of the gel filtration step. Peak fractions of the Co2+-affinity purified 
proteins were loaded onto a Superdex 200 16/60 column. Elution fractions (2.5 ml) are 
indicated on the horizontal axis. (D) Analysis of gel filtration elution fractions. Samples were 
separated by 14% SDS-PAGE and stained with Coomassie Blue. Indicated are the load (L) 
and elution fractions. Peak fractions containing aggregates (I), trimeric His•BTG2-Caf1-
Ccr4b complexes (II) and dimeric His•BTG2-Caf1 complexes (III) are highlighted with 
asterisks. (E) Alternative purification strategy based on co-expression of His•BTG2, Caf1 and 
GST•Ccr4b followed by subsequent immobilised-metal and glutathione affinity 
chromatography.  (F) Purification of His•BTG2-Caf1-GST•Ccr4b by subsequent 
immobilised-metal (lane 1) and glutathione affinity chromatography (lane 2).  Proteins were 
separated by 14% SDS-PAGE and stained with Coomassie Blue.  
 
Figure 2. Comparison of deadenylase activities of Caf1, BTG2-Caf1, Ccr4b LRR and 
the trimeric BTG2-Caf1-Ccr4b complex 
(A) Analysis of purified deadenylase subunits and protein complexes. Purified Caf1, 
Ccr4b LRR, dimeric BTG2-Caf1 and trimeric BTG2-Caf1-Ccr4b complexes (2.0 µg) were 
separated by 14% SDS-PAGE and stained with SYPRO Ruby. (B) Immunoblot analysis of 
purified deadenylase subunits and protein complexes. Purified Caf1, Ccr4b LRR, BTG2-
Caf1 and BTG2-Caf1-Ccr4b proteins were separated by 14% SDS-PAGE and transferred to 
nitrocellulose membranes. Proteins were detected by immunoblotting using antibodies 
recognising Ccr4b (top) and Caf1 (bottom). (C) Comparison of the deadenylase activity of 
purified Caf1, Ccr4b LRR, BTG2-Caf1 and BTG2-Caf1-Ccr4b. The indicated amount of 
protein was incubated at 30°C for 60 min. Error bars indicate the standard error of the mean 
(n=3). 
 
Figure 3. The catalytic activities of Caf1 and Ccr4b are both required for deadenylation 
by the BTG2-Caf1-Ccr4b nuclease module 
(A) Purification of BTG2-Caf1-Ccr4b nuclease modules containing catalytically inactive 
deadenylase subunits. Amino acid substitutions abolishing the nuclease activity of Caf1 
(D40A) or Ccr4b (E240A) are indicated. Proteins (2.0 µg) were separated by 14% SDS-
PAGE and stained with Coomassie Blue. Minor contaminants are indicated by asterisks. (B) 
Immunoblot analysis of purified His•BTG2-Caf1-GST•Ccr4b nuclease sub-complexes. 
Proteins were detected using antibodies recognising Ccr4b, Caf1 and BTG2. (C) Comparison 
of the deadenylase activity of purified BTG2-Caf1-Ccr4b complexes. Amino acid 
substitutions inactivating the nuclease activity of Caf1 (D40A) and Ccr4b (E240A) are 
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indicated. The indicated amount of protein was incubated at 30°C for 60 min. Error bars 
indicate the standard error of the mean (n=3). (D) Product analysis by polyacrylamide gel 
electrophoresis. A fluorescent RNA oligonucleotide containing nine terminal adenosine 
residues (A9) was used as a substrate for purified BTG2-Caf1-Ccr4b complexes. Proteins 
(450 nM) were incubated with RNA substrate (1.0 µM) at 30°C for 60 min. Amino acid 
substitutions abolishing the nuclease activities of Caf1 (D40A) and Ccr4b (E240A) and the 
positions of the intact RNA substrate (A9) and the degradation product (A1) are indicated. 
 
Figure 4. Selective inhibitors of Caf1 inhibit the deadenylase activity of the BTG2-Caf1-
Ccr4b trimeric nuclease module 
(A) Structure and IC50 values of selective inhibitors of Caf1. IC50 values were determined 
using isolated Caf1 [45]. (B) The deadenylase activity of the trimeric BTG2-Caf1-Ccr4b 
complex was assessed in the presence of the indicated compounds (300 µM final 
concentration). Protein complexes were pre-incubated with the indicated compounds at room 
temperature for 15 min. After addition of Flc-labelled substrate RNA, reactions were 
incubated at 30⁰C for 60 min. Fluorescence was measured after addition of a mixture 
containing SDS (0.5% final concentration) and a five-fold molar excess of TAMRA-labelled 
probe. Error bars indicate the standard error of the mean (n=3). (C) Product analysis using 
polyacrylamide gel electrophoresis. A fluorescent RNA oligonucleotide containing nine 
terminal adenosine residues (A9) was used as a substrate for purified BTG2-Caf1-Ccr4b 
complexes (450 nM). The positions of the intact RNA substrate (A9) and the degradation 
product (A1) are indicated. 
 
Figure 5. Deadenylation by the BTG2-Caf1-Ccr4a complex 
(A) Analysis of purified wild type and inactive Ccr4a LRR and Ccr4b LRR. The 
inactivating amino acid substitution E240A is indicated. Proteins were expressed in E. coli 
and purified by immobilised metal affinity chromatography. Proteins (2.0 µg) were analysed 
by 14% SDS-PAGE and stained with Coomassie Blue. (B) Comparison of the deadenylase 
activities of Ccr4a LRR  and Ccr4b LRR. Increasing amounts of the indicated proteins 
were incubated at 30°C for 60 min. Error bars indicate the standard error of the mean (n=3). 
(C) Time-course comparison of Ccr4a LRR  and Ccr4b LRR. The indicated proteins 
(1.0 µM) were incubated at 30°C for the indicated amount of time. Error bars indicate the 
standard error of the mean (n=3). (D) Purification of BTG2-Caf1-Ccr4a nuclease modules 
lacking catalytically active deadenylase subunits. Amino acid substitutions abolishing the 
nuclease activity of Caf1 (D40A) and Ccr4a (E240A) are indicated. Proteins (2.0 µg) were 
separated by 14% SDS-PAGE and stained with Coomassie Blue. (E) Immunoblot analysis of 
purified BTG2-Caf1-Ccr4a nuclease sub-complexes. Proteins were detected using antibodies 
recognising Ccr4a, Caf1 and BTG2. (F) Comparison of the deadenylase activity of purified 
BTG2-Caf1-Ccr4a complexes. Amino acid substitutions disabling the nuclease activity of 
Caf1 (D40A) and Ccr4a (E240A) are indicated. Proteins were incubated at 30°C for 60 min. 
Error bars indicate the standard error of the mean (n=3). (G) Product analysis by 
polyacrylamide gel electrophoresis. A fluorescent RNA oligonucleotide containing nine 
adenosines (A9) was used as a substrate for purified BTG2-Caf1-Ccr4a complexes. Proteins 
(350 nM) were incubated with RNA substrate (1.0 µM) at 30°C for 60 min. Amino acid 
13 
 
substitutions inactivating the nuclease activity of Caf1 (D40A) and Ccr4a (E240A) and the 
positions of the intact RNA substrate (A9) and the degradation product (A1) are indicated. 
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